Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine.

摘要: Although, in recent decades effectivechemotherapy regimens have been developed forthe treatment of Hodgkin's disease, theprognosis patients who experiencedisease progression is still very poor. Newtreatment approaches are urgently required tosalvage such patients. In a patient withHodgkin's disease failed to achievecomplete remission with the escalatedBEACOPP protocol, bonemarrow infiltration and B symptomsdeveloped despite further treatment.Subsequently, gemcitabine was administeredin novel schedule as four-hour infusion of250 mg/m2 on days 1, 8, 15, every four weeks.After first cycle, dose reducedto 200 because grade 3neutropenia. The condition patientimproved after second cycle notoxicity observed during cycles 3–6.Complete achieved. Twoyears end gemcitabinetherapy, good clinicalcondition continuous completeremission without treatment. Thisis report prolonged infusionof salvage therapy inHodgkin's disease.